Form 4: Director Ferrara Acquires PHIO Stock Units

Phio Pharmaceuticals Director Robert L. Ferrara acquired 23,000 restricted stock units, increasing his beneficial ownership to 38,666 shares.

Summary

• Robert L. Ferrara, a Director of Phio Pharmaceuticals Corp. (PHIO), acquired 23,000 shares of common stock on September 11, 2025.
• These shares represent restricted stock units (RSUs) that will vest on the first annual anniversary of the grant.
• Following this transaction, Ferrara beneficially owns 38,666 shares of common stock.
• The reported share count has been adjusted for prior reverse stock splits.
• Ferrara also granted a Power of Attorney to Lisa C. Carson (Phio Pharmaceuticals Corp.) and Irina Abbas (Hogan Lovells US LLP) for SEC filing purposes, effective September 4, 2025.

Sentiment

Score: 7

Explanation: The filing indicates a routine equity compensation grant to a director, aligning interests with shareholders. While not an open market purchase, it reflects continued commitment. The Power of Attorney is a procedural document. No negative financial news is present, but also no immediate positive catalysts beyond standard compensation.

Positives

• Director Robert L. Ferrara increased his beneficial ownership in Phio Pharmaceuticals by acquiring 23,000 restricted stock units.
• The grant of restricted stock units aligns management incentives with long-term shareholder value through future vesting.

Negatives

• The acquired shares are restricted stock units, meaning they are not immediately liquid and vest over time.
• The transaction price for the acquired shares was $0, indicating a grant rather than an open market purchase, which might be viewed differently by some investors.

Risks

• The value of the restricted stock units is subject to the future performance of Phio Pharmaceuticals' common stock.
• The vesting schedule (first annual anniversary of the grant) means the director's full ownership is contingent on continued service and company performance.

Future Outlook

The 23,000 restricted stock units granted to Director Ferrara are scheduled to vest on the first annual anniversary of the grant, indicating a future milestone for his equity compensation.

Industry Context

This transaction is a routine insider filing (Form 4) for equity compensation, common across publicly traded companies to align director interests with shareholders. The grant of restricted stock units is a standard practice for executive and director compensation in the biotechnology/pharmaceutical industry, where long-term value creation is emphasized.

Comparison to Industry Standards

• The use of restricted stock units (RSUs) for director compensation is a common practice in the biotechnology and pharmaceutical sectors, similar to companies like Moderna or Pfizer, which often use equity awards to incentivize long-term commitment and performance.
• The vesting schedule of one year for the RSUs is a typical short-to-medium term vesting period for such grants, comparable to practices seen at many small-to-mid cap biotech firms.
• The adjustment for prior reverse stock splits is a common occurrence for companies that have undergone such corporate actions, ensuring accurate reporting of beneficial ownership.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of restricted stock units to a director aligns management's long-term interests with shareholder value, as the value of the compensation is tied to the company's stock performance.
• Management/Directors: Robert L. Ferrara receives equity compensation, incentivizing his continued service and performance. The Power of Attorney simplifies his compliance with SEC reporting requirements.

Next Steps

• The 23,000 restricted stock units are expected to vest on the first annual anniversary of the grant.
• Robert L. Ferrara will continue to file SEC forms (e.g., Forms 3, 4, 5) as required, facilitated by the granted Power of Attorney.

Key Dates

Recommendation

This filing details a routine equity compensation grant to a director and a procedural power of attorney. It does not contain information that would fundamentally alter the investment thesis for Phio Pharmaceuticals. While insider ownership is generally positive, this is a grant, not an open market purchase, and therefore does not signal a strong conviction buy. Investors should hold and await more substantive operational or financial news.

Keywords

Phio Pharmaceuticals, PHIO, Robert L. Ferrara, Director, Restricted Stock Units, RSU, Insider Trading, SEC Filing, Form 4, Beneficial Ownership, Equity Compensation